Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma (ABUS) reported Q2 2026 results and said the FDA aligned with its proposed Phase 2b trial design for imdusiran in chronic hepatitis B, following Fast Track designation. The company received about $178.4 million from its Moderna settlement share and plans potential share repurchases up to about $230 million. Q2 revenue was $1.0 million; net loss $5.1 million.

Arbutus Biopharma (Nasdaq: ABUS) reported Q2 2026 results, with cash, cash equivalents and marketable securities of $92.6M at June 30, 2026. Q2 revenue fell to $1.0M from $10.7M year over year, and net loss was $5.1M. In July it received $178.4M from a Moderna settlement, expects up to $230M in share repurchases, and aligned with the FDA on a Phase 2b imdusiran trial design.

Arbutus Biopharma Corp (ABUS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026 Received first

Arbutus Biopharma (ABUS) received about $178 million from Moderna (MRNA) as its share of a $950 million noncontingent LNP patent settlement, with reimbursement of legal costs and an expected Q3 dividend tied to Genevant. ABUS reported Q1 2026 revenue of $179.1 million and net income of $169.7 million. Moderna reported Q2 2026 revenue of $145 million and a net loss of $782 million, plus FDA approval for mFLUSIVA.

Arbutus Biopharma (ABUS) and Genevant Sciences, a Roivant unit, filed three international patent lawsuits against Pfizer and BioNTech to enforce LNP patents tied to mRNA-LNP COVID-19 vaccines, seeking monetary relief and injunctions. Arbutus said it received about $178 million from Moderna under a settlement and expects a Genevant-parent dividend in Q3 2026, plus share repurchases up to about $230 million starting Q3 2026.

ExxonMobil Mozambique, on behalf of the Area 4 co-venturers, awarded about $1.1 billion in pre-investment contracts for long-lead equipment for the Rovuma LNG Phase 1 project in Cabo Delgado, to support a future final investment decision. Contracts cover subsea production systems, valves, and offshore line pipe, including work by OneSubsea, Aker Solutions, and others.